Therefore, we considered that interference between the NS3 domain and its cofactor, NS2B (Figure 2A), might be a superior drug target to stabilize the inactive “super-open” conformation in the design of allosteric novel highly potent and specific small molecules for ZIKV infection treatment. The gene discussed is KRAS; the disease is Zika virus infectious disease.